drugset / Trial / NCT06575595
Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010)
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objectives of the study are to characterize the pharmacokinetics (PK) of a single subcutaneous (SC) dose of tulisokibart (MK-7240) administered via autoinjector (AI) (Treatment A) and to characterize the PK of different concentrations of tulisokibart following SC administration of a single dose via vial/syringe (Treatments B and C). There is no formal hypothesis.
Timeline
- Start
- 2024-09-24
- Primary completion
- 2025-01-31
- Completion
- 2025-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tulisokibart | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.